ATRICURE INC (ATRC) Stock News
NASDAQ:ATRC - Nasdaq - US04963C2098 - Common Stock - Currency: USD
ATRC Latest News, Press Relases and Analysis
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
Here is how Astellas Pharma Inc. (ALPMY) and AtriCure (ATRC) have performed compared to their sector so far this year.
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect?
The consensus price target hints at a 54.7% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
AtriCure (ATRC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of 44% and 0.16%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Steve Seedhouse assumed coverage of ProQR Therapeutics (PRQR) with an Overweight rating and $8 price target ProQR is a leader in RNA editing and the initial biomarker data for its first program targeting bile acid transporter in Q4 will be an “important catalyst,” the analyst tells investors in a research note. Cantor views the company as a “pure play” on RNA editing. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. T
AtriCure Reports First Quarter 2025 Financial Results
AtriCure Announces First Use of the AtriClip PRO-Mini® Device
AtriCure to Announce First Quarter 2025 Financial Results
AtriCure to Host Analyst & Investor Day on March 26, 2025
AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results
AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results
AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference
AtriCure to Participate in the Stifel 2024 Healthcare Conference
AtriCure Reports Third Quarter 2024 Financial Results
AtriCure to Participate in the UBS Global Healthcare Conference
AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management
AtriCure to Announce Third Quarter 2024 Financial Results
